The research in this paper looks into the issues of access and efficiency brought to the fore as a result of pharmaceutical mergers and acquisitions in emerging markets. The research also analyses the nature of competition law in emerging markets.
Last Update: 19.04.16
Pharmaceutical M&As in emerging markets may jeopardize cheap access to generics. This may be a motivation for policy makers to use competition law as a tool to deter cross-border M&As. Additionally, while M&As in the pharmaceutical sector may give rise to certain efficiencies, it is not clear how efficiencies will be treated in the peculiar socio-economic context of emerging markets. This paper develops a theoretical framework that argues that the application of competition law is guided by sector-specific socio-economic realities and institutional realities of the jurisdiction. Thereafter, it employs this framework to analyze the issues of access to generics and efficiencies of production.
Vikas Kathuria
Dr. Mark-Oliver Mackenrodt
Dr. Pierre Larouche
Globale Wettbewerbsordnung
